We demonstrate that IGFBP‐4 exerts antifibrotic effects as demonstrated in vitro using primary human pulmonary fibroblasts, in vivo using the murine bleomycin model of pulmonary fibrosis, and ex vivo using human skin and lung tissues in organ culture. The gene discussed is IGFBP4; the disease is pulmonary fibrosis.